vs
Side-by-side financial comparison of Royal Caribbean Group (RCL) and Zoetis (ZTS). Click either name above to swap in a different company.
Royal Caribbean Group is the larger business by last-quarter revenue ($4.3B vs $2.4B, roughly 1.8× Zoetis). Zoetis runs the higher net margin — 25.3% vs 17.7%, a 7.6% gap on every dollar of revenue. On growth, Royal Caribbean Group posted the faster year-over-year revenue change (13.3% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $116.0M). Over the past eight quarters, Royal Caribbean Group's revenue compounded faster (6.9% CAGR vs 4.4%).
Royal Caribbean Group, formerly known as Royal Caribbean Cruises Ltd., is a cruise holding company headquartered in Miami, Florida, United States and incorporated in Liberia. It is the world's second-largest cruise line operator, after Carnival Corporation & plc. As of September 2025, Royal Caribbean Group fully owns three cruise lines: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. It also holds a 50% stake in TUI Cruises, which operates Mein Schiff and Hapag-Lloyd ...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
RCL vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.3B | $2.4B |
| Net Profit | $753.0M | $603.0M |
| Gross Margin | 47.4% | 70.2% |
| Operating Margin | 21.9% | 31.9% |
| Net Margin | 17.7% | 25.3% |
| Revenue YoY | 13.3% | 3.0% |
| Net Profit YoY | 36.4% | 3.8% |
| EPS (diluted) | $2.76 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.3B | $2.4B | ||
| Q3 25 | $5.1B | $2.4B | ||
| Q2 25 | $4.5B | $2.5B | ||
| Q1 25 | $4.0B | $2.2B | ||
| Q4 24 | $3.8B | $2.3B | ||
| Q3 24 | $4.9B | $2.4B | ||
| Q2 24 | $4.1B | $2.4B | ||
| Q1 24 | $3.7B | $2.2B |
| Q4 25 | $753.0M | $603.0M | ||
| Q3 25 | $1.6B | $721.0M | ||
| Q2 25 | $1.2B | $718.0M | ||
| Q1 25 | $730.0M | $631.0M | ||
| Q4 24 | $552.0M | $581.0M | ||
| Q3 24 | $1.1B | $682.0M | ||
| Q2 24 | $854.0M | $624.0M | ||
| Q1 24 | $360.0M | $599.0M |
| Q4 25 | 47.4% | 70.2% | ||
| Q3 25 | 51.8% | 71.5% | ||
| Q2 25 | 49.7% | 73.6% | ||
| Q1 25 | 48.0% | 72.0% | ||
| Q4 24 | 45.4% | 69.5% | ||
| Q3 24 | 51.1% | 70.6% | ||
| Q2 24 | 47.6% | 71.7% | ||
| Q1 24 | 44.8% | 70.6% |
| Q4 25 | 21.9% | 31.9% | ||
| Q3 25 | 33.1% | 37.0% | ||
| Q2 25 | 29.3% | 36.7% | ||
| Q1 25 | 23.6% | 36.5% | ||
| Q4 24 | 16.6% | 31.6% | ||
| Q3 24 | 33.4% | 36.6% | ||
| Q2 24 | 26.7% | 33.0% | ||
| Q1 24 | 20.1% | 34.1% |
| Q4 25 | 17.7% | 25.3% | ||
| Q3 25 | 30.6% | 30.0% | ||
| Q2 25 | 26.7% | 29.2% | ||
| Q1 25 | 18.3% | 28.4% | ||
| Q4 24 | 14.7% | 25.1% | ||
| Q3 24 | 22.7% | 28.6% | ||
| Q2 24 | 20.8% | 26.4% | ||
| Q1 24 | 9.7% | 27.4% |
| Q4 25 | $2.76 | $1.37 | ||
| Q3 25 | $5.74 | $1.63 | ||
| Q2 25 | $4.41 | $1.61 | ||
| Q1 25 | $2.70 | $1.41 | ||
| Q4 24 | $2.27 | $1.29 | ||
| Q3 24 | $4.21 | $1.50 | ||
| Q2 24 | $3.11 | $1.37 | ||
| Q1 24 | $1.35 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $825.0M | — |
| Total DebtLower is stronger | $18.2B | — |
| Stockholders' EquityBook value | $10.0B | $3.3B |
| Total Assets | $41.6B | $15.5B |
| Debt / EquityLower = less leverage | 1.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $825.0M | — | ||
| Q3 25 | $432.0M | $2.1B | ||
| Q2 25 | $735.0M | $1.4B | ||
| Q1 25 | $386.0M | $1.7B | ||
| Q4 24 | $388.0M | $2.0B | ||
| Q3 24 | $418.0M | $1.7B | ||
| Q2 24 | $391.0M | $1.6B | ||
| Q1 24 | $437.0M | $2.0B |
| Q4 25 | $18.2B | — | ||
| Q3 25 | $17.2B | — | ||
| Q2 25 | $17.6B | — | ||
| Q1 25 | $18.0B | — | ||
| Q4 24 | $18.5B | — | ||
| Q3 24 | $19.0B | — | ||
| Q2 24 | $19.8B | — | ||
| Q1 24 | $18.9B | — |
| Q4 25 | $10.0B | $3.3B | ||
| Q3 25 | $10.1B | $5.4B | ||
| Q2 25 | $9.2B | $5.0B | ||
| Q1 25 | $8.0B | $4.7B | ||
| Q4 24 | $7.6B | $4.8B | ||
| Q3 24 | $7.0B | $5.2B | ||
| Q2 24 | $6.0B | $5.0B | ||
| Q1 24 | $5.2B | $5.1B |
| Q4 25 | $41.6B | $15.5B | ||
| Q3 25 | $40.1B | $15.2B | ||
| Q2 25 | $38.5B | $14.5B | ||
| Q1 25 | $37.5B | $14.1B | ||
| Q4 24 | $37.1B | $14.2B | ||
| Q3 24 | $37.1B | $14.4B | ||
| Q2 24 | $37.0B | $14.2B | ||
| Q1 24 | $35.2B | $14.3B |
| Q4 25 | 1.81× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.26× | — | ||
| Q4 24 | 2.44× | — | ||
| Q3 24 | 2.69× | — | ||
| Q2 24 | 3.29× | — | ||
| Q1 24 | 3.66× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $893.0M |
| Free Cash FlowOCF − Capex | $116.0M | $732.0M |
| FCF MarginFCF / Revenue | 2.7% | 30.7% |
| Capex IntensityCapex / Revenue | 35.4% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.16× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $893.0M | ||
| Q3 25 | $1.5B | $938.0M | ||
| Q2 25 | $1.7B | $486.0M | ||
| Q1 25 | $1.6B | $587.0M | ||
| Q4 24 | $1.5B | $905.0M | ||
| Q3 24 | $897.0M | $951.0M | ||
| Q2 24 | $1.6B | $502.0M | ||
| Q1 24 | $1.3B | $595.0M |
| Q4 25 | $116.0M | $732.0M | ||
| Q3 25 | $-989.0M | $805.0M | ||
| Q2 25 | $910.0M | $308.0M | ||
| Q1 25 | $1.2B | $438.0M | ||
| Q4 24 | $915.0M | $689.0M | ||
| Q3 24 | $563.0M | $784.0M | ||
| Q2 24 | $-567.0M | $370.0M | ||
| Q1 24 | $1.1B | $455.0M |
| Q4 25 | 2.7% | 30.7% | ||
| Q3 25 | -19.2% | 33.5% | ||
| Q2 25 | 20.1% | 12.5% | ||
| Q1 25 | 30.0% | 19.7% | ||
| Q4 24 | 24.3% | 29.7% | ||
| Q3 24 | 11.5% | 32.8% | ||
| Q2 24 | -13.8% | 15.7% | ||
| Q1 24 | 29.1% | 20.8% |
| Q4 25 | 35.4% | 6.7% | ||
| Q3 25 | 47.8% | 5.5% | ||
| Q2 25 | 18.4% | 7.2% | ||
| Q1 25 | 10.7% | 6.7% | ||
| Q4 24 | 14.7% | 9.3% | ||
| Q3 24 | 6.8% | 7.0% | ||
| Q2 24 | 52.1% | 5.6% | ||
| Q1 24 | 6.5% | 6.4% |
| Q4 25 | 2.16× | 1.48× | ||
| Q3 25 | 0.93× | 1.30× | ||
| Q2 25 | 1.44× | 0.68× | ||
| Q1 25 | 2.23× | 0.93× | ||
| Q4 24 | 2.66× | 1.56× | ||
| Q3 24 | 0.81× | 1.39× | ||
| Q2 24 | 1.84× | 0.80× | ||
| Q1 24 | 3.69× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RCL
| Passenger | $2.9B | 69% |
| Other | $1.3B | 31% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
